We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BrightSpring Q3 Earnings Beat on Specialty Growth, '26 View Raised
Read MoreHide Full Article
Key Takeaways
BrightSpring's Q3 adjusted EPS jumped 80% to 54 cents, while revenues climbed 26.4% to $4.21 billion.
Specialty and Infusion revenues surged 33.8%, while Home Health Care revenues rose 52.4% year over year.
BTSG raised its 2026 revenue guidance to $15.90-$16.13B and adjusted EBITDA outlook to $850-$860 million.
BrightSpring Health Services, Inc. (BTSG - Free Report) reported third-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which beat the Zacks Consensus Estimate of 49 cents by 10.2%. The bottom line improved 80% year over year.
GAAP EPS from continuing operations was 46 cents, up from 17 cents in the year-ago quarter.
BTSG’s Q3 Revenue Details
Revenues increased 26.4% year over year to $4.21 billion, surpassing the Zacks Consensus Estimate of $3.86 billion by 9.2%. Growth was driven by strong Specialty and Infusion performance, including 29% prescription growth, alongside expanding Home Health Care volumes.
Year to date, BTSG’s shares have rallied 78.6%, outperforming the industry’s 10% gain and the broader S&P 500 Index’s 9.3% increase.
Image Source: Zacks Investment Research
BTSG's Pharmacy Solutions Revenues Grow
Pharmacy Solutions revenues totaled $3.73 billion, up 25.8% year over year. Growth was driven by Specialty and Infusion Pharmacy, supported by branded limited distribution drugs (LDDs), generic utilization, pharmaceutical services and higher prescription volumes.
Specialty and Infusion revenues increased 33.8% to $3.18 billion. BrightSpring launched seven LDDs during the quarter, bringing year-to-date launches to 19 and its total portfolio to 162. Management noted that the annualized revenue contribution from 2026 launches is tracking ahead of the prior year's launches at the same stage.
However, Home and Community Pharmacy revenues declined 6.3% to $553 million. The decrease reflected an approximately $50 million impact from the Inflation Reduction Act (IRA) and the company's decision to exit uneconomic customer relationships. Despite revenue pressure, operational improvements supported double-digit EBITDA growth in this business.
Provider Services revenues totaled $481 million, up 31% year over year. Growth was primarily driven by Home Health Care, supported by higher patient volumes, new locations and contributions from acquired Amedisys and LHC branches.
Home Health Care revenues increased 52.4% to $288 million. The acquired branches contributed approximately $76 million in quarterly revenues. Excluding these acquisitions, Home Health Care revenue growth was 12%. Average daily census increased 57.6% to 47,256 patients.
Rehab Care revenues increased 8.3% to $82 million, supported by higher patient volumes and hours billed. Persons served increased 9.3% to 7,574. Personal Care revenues improved 8.1% to $111 million, while persons served increased 1.2% to 16,320.
BrightSpring's Pharmacy Operating Metrics Improve
Total prescriptions dispensed increased 1.5% year over year to approximately 10.95 million. Revenue per prescription climbed 24% to $340.86, while gross profit per prescription increased 26.8% to $28.86.
Management attributed the improvement in gross profit per prescription primarily to favorable business mix, particularly stronger Specialty and Infusion volumes. The company continues to prioritize absolute gross profit and EBITDA growth rather than individual prescription economics.
BrightSpring also reported mid-teens prescription growth across acute and chronic infusion therapies. Investments in infusion capabilities, technology and pharmaceutical service programs continue to support expansion across its pharmacy operations.
BrightSpring Expands Margins
Gross profit was $518.5 million, up 32.3% year over year. As a percentage of revenues, the gross margin was 12.3%, up 50 basis points (bps) from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $358.1 million, up 17.7% year over year.
Operating income totaled $160.5 million, up 82.7% year over year. As a percentage of revenues, the operating margin was 3.8%, up 120 bps from the prior-year quarter’s figure.
BTSG’s Financial Position
BrightSpring exited the third quarter with cash and cash equivalents of $717.8 million compared with $550.4 million in the previous quarter.
Total assets increased to $6.27 billion from $5.99 billion in the previous quarter.
Cumulative net cash provided by operating activities at the end of third-quarter 2026 was $371.2 million compared with $258.6 million in the year-ago period.
BrightSpring Health Services, Inc. Price, Consensus and EPS Surprise
BrightSpring raised its full-year 2026 revenue guidance to $15.90-$16.13 billion from the previous range of $15.10-$15.43 billion. The updated outlook implies revenue growth of 23.2%-24.9%.
Pharmacy Solutions revenues are now projected at $14.00-$14.20 billion, compared with the previous guidance of $13.20-$13.50 billion. Provider Services revenues are expected to be between $1.90 billion and $1.93 billion.
Adjusted EBITDA guidance increased to $850-$860 million from $820-$845 million, implying year-over-year growth of 37.6%-39.3%. The outlook includes approximately $35 million in contributions from the Amedisys and LHC acquisitions.
Management expects operating cash flow of at least $700 million for 2026, excluding Community Living transaction-related impacts. BrightSpring reiterated its expectation of at least 15%-20% organic adjusted EBITDA growth in 2027, supported by continued operational execution and expansion opportunities.
BTSG’s Zacks Rank & Key Picks
BrightSpring currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
BrightSpring Q3 Earnings Beat on Specialty Growth, '26 View Raised
Key Takeaways
BrightSpring Health Services, Inc. (BTSG - Free Report) reported third-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which beat the Zacks Consensus Estimate of 49 cents by 10.2%. The bottom line improved 80% year over year.
GAAP EPS from continuing operations was 46 cents, up from 17 cents in the year-ago quarter.
BTSG’s Q3 Revenue Details
Revenues increased 26.4% year over year to $4.21 billion, surpassing the Zacks Consensus Estimate of $3.86 billion by 9.2%. Growth was driven by strong Specialty and Infusion performance, including 29% prescription growth, alongside expanding Home Health Care volumes.
Year to date, BTSG’s shares have rallied 78.6%, outperforming the industry’s 10% gain and the broader S&P 500 Index’s 9.3% increase.
Image Source: Zacks Investment Research
BTSG's Pharmacy Solutions Revenues Grow
Pharmacy Solutions revenues totaled $3.73 billion, up 25.8% year over year. Growth was driven by Specialty and Infusion Pharmacy, supported by branded limited distribution drugs (LDDs), generic utilization, pharmaceutical services and higher prescription volumes.
Specialty and Infusion revenues increased 33.8% to $3.18 billion. BrightSpring launched seven LDDs during the quarter, bringing year-to-date launches to 19 and its total portfolio to 162. Management noted that the annualized revenue contribution from 2026 launches is tracking ahead of the prior year's launches at the same stage.
However, Home and Community Pharmacy revenues declined 6.3% to $553 million. The decrease reflected an approximately $50 million impact from the Inflation Reduction Act (IRA) and the company's decision to exit uneconomic customer relationships. Despite revenue pressure, operational improvements supported double-digit EBITDA growth in this business.
BrightSpring's Provider Services Maintain Momentum
Provider Services revenues totaled $481 million, up 31% year over year. Growth was primarily driven by Home Health Care, supported by higher patient volumes, new locations and contributions from acquired Amedisys and LHC branches.
Home Health Care revenues increased 52.4% to $288 million. The acquired branches contributed approximately $76 million in quarterly revenues. Excluding these acquisitions, Home Health Care revenue growth was 12%. Average daily census increased 57.6% to 47,256 patients.
Rehab Care revenues increased 8.3% to $82 million, supported by higher patient volumes and hours billed. Persons served increased 9.3% to 7,574. Personal Care revenues improved 8.1% to $111 million, while persons served increased 1.2% to 16,320.
BrightSpring's Pharmacy Operating Metrics Improve
Total prescriptions dispensed increased 1.5% year over year to approximately 10.95 million. Revenue per prescription climbed 24% to $340.86, while gross profit per prescription increased 26.8% to $28.86.
Management attributed the improvement in gross profit per prescription primarily to favorable business mix, particularly stronger Specialty and Infusion volumes. The company continues to prioritize absolute gross profit and EBITDA growth rather than individual prescription economics.
BrightSpring also reported mid-teens prescription growth across acute and chronic infusion therapies. Investments in infusion capabilities, technology and pharmaceutical service programs continue to support expansion across its pharmacy operations.
BrightSpring Expands Margins
Gross profit was $518.5 million, up 32.3% year over year. As a percentage of revenues, the gross margin was 12.3%, up 50 basis points (bps) from the prior-year quarter’s figure.
Selling, general and administrative expenses totaled $358.1 million, up 17.7% year over year.
Operating income totaled $160.5 million, up 82.7% year over year. As a percentage of revenues, the operating margin was 3.8%, up 120 bps from the prior-year quarter’s figure.
BTSG’s Financial Position
BrightSpring exited the third quarter with cash and cash equivalents of $717.8 million compared with $550.4 million in the previous quarter.
Total assets increased to $6.27 billion from $5.99 billion in the previous quarter.
Cumulative net cash provided by operating activities at the end of third-quarter 2026 was $371.2 million compared with $258.6 million in the year-ago period.
BrightSpring Health Services, Inc. Price, Consensus and EPS Surprise
BrightSpring Health Services, Inc. price-consensus-eps-surprise-chart | BrightSpring Health Services, Inc. Quote
BrightSpring Raises 2026 Guidance
BrightSpring raised its full-year 2026 revenue guidance to $15.90-$16.13 billion from the previous range of $15.10-$15.43 billion. The updated outlook implies revenue growth of 23.2%-24.9%.
Pharmacy Solutions revenues are now projected at $14.00-$14.20 billion, compared with the previous guidance of $13.20-$13.50 billion. Provider Services revenues are expected to be between $1.90 billion and $1.93 billion.
Adjusted EBITDA guidance increased to $850-$860 million from $820-$845 million, implying year-over-year growth of 37.6%-39.3%. The outlook includes approximately $35 million in contributions from the Amedisys and LHC acquisitions.
Management expects operating cash flow of at least $700 million for 2026, excluding Community Living transaction-related impacts. BrightSpring reiterated its expectation of at least 15%-20% organic adjusted EBITDA growth in 2027, supported by continued operational execution and expansion opportunities.
BTSG’s Zacks Rank & Key Picks
BrightSpring currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.